ArticleJMIR formative research2020
Reasons People Who Use Opioids Do Not Accept or Carry No-Cost Naloxone: Qualitative Interview Study.
Article in JMIR formative research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 86 citations in OpenAlex.
- Organizational perspectives on the impacts of scaling up overdose education and naloxone distribution in Kentucky.Addiction science & clinical practice · 2025Trial
- "I'm not going to lay back and watch somebody die": a qualitative study of how people who use drugs' naloxone experiences are shaped by rural risk environment and overdose education/naloxone distribution intervention.Harm reduction journal · 2023Trial
- Effects of opioids and stimulants on the respiratory system.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Public perceptions and willingness-to-pay regarding over-the-counter (OTC) naloxone: A national cross-sectional survey informed by the Theory of Planned Behavior.Exploratory research in clinical and social pharmacy · 2026Article
- Syringe service program utilization, behavioral, and experiential factors associated with greater naloxone protection in a longitudinal cohort of people who use illicit opioids in New York city.Harm reduction journal · 2026Article
- Reciprocal influences between overdose experiences and naloxone access among people who use drugs utilizing a syringe services program: a cross-lagged panel model.Harm reduction journal · 2026Article
- Polydrug overdose mortality caused by synthetic opioids and stimulants: current sex- and age-specific trajectories in United States national data for 2018-2024.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Assessing knowledge, attitudes, and barriers to opioid overdose among college students.BMC public health · 2026Article
- Mechanisms of overdose from unintentional fentanyl use when intending to use stimulants: a qualitative study of people who use stimulants and avoid opioids.Research square · 2026Article
- "Extremely cheap and extremely potent": Fentanyl Knowledge and Risk Practices AmongYoung People in Oregon Who Have Used Non-Prescription Pills.Research square · 2026Article
- A descriptive study of drug overdose epidemics, overdose prevention efforts, and opioid settlement fund distribution across six states.The International journal on drug policy · 2026Article
- "Let's Talk Stigma": A Pharmacy-Based Program for Opioid Use Disorder Anti-Stigma Education in Pennsylvania.Pharmacy (Basel, Switzerland) · 2025Article
- Associations Between Healthcare Providers' Stigmatizing Attitudes Toward People Living with HIV and People Who Use Drugs: A Canonical Correlation Analysis.AIDS and behavior · 2025Article
- Syringe Service Program Utilization, Behavioral, and Experiential Factors Associated with Greater Naloxone Protection in a Longitudinal Cohort of People Who Use Illicit Opioids in New York City.Research square · 2025Article
- Impact of a brief personally tailored opioid-overdose and medication for opioid use disorder education intervention on naloxone acceptance in peripartum individuals: A secondary exploratory analysis.Journal of substance use and addiction treatment · 2025Article
- Naloxone Use, 911 Calls, and Emergency Visits After Nonfatal Overdose.JAMA network open · 2025Article
- "We're Not Gonna Aid You in Shooting Up": Stigma's Relationship to Harm Reduction in People Who Inject Drugs.Journal of general internal medicine · 2025Article
- Having naloxone when you need it: Factors associated with owning and carrying naloxone among people who use opioids.The International journal on drug policy · 2025Article
- Naloxone Acceptance among Nightclub Attendees in New York City.Journal of community health · 2025Article
- Access to Naloxone and Preferences for Its Online Purchase Among Individuals Affected by Opioid Misuse.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundMany people use opioids and are at risk of overdose. Naloxone is an opioid antagonist used to counter the effects of opioid overdose. There is an increased availability of naloxone in New York City; however, many who use opioids decline no-cost naloxone even when offered. Others may have the medication but opt not to carry it and report that they would be reluctant to administer it if they were to witness an overdose.
objectiveWe aim to better understand why people who use opioids may be reluctant to accept, carry, and administer naloxone, and to inform the development of messaging content that addresses barriers to its acceptance and use.
methodsWe conducted formative qualitative interviews with 20 people who use opioids who are 18 years and older in New York City. Participants were recruited via key informants and chain referral.
resultsParticipants cited 4 main barriers that may impede rates of naloxone acceptance, possession, and use: (1) stigma related to substance use, (2) indifference toward overdose, (3) fear of negative consequences of carrying naloxone, and (4) fear of misrecognizing the need for naloxone. Participants also offered suggestions about messaging content to tackle the identified barriers, including messages designed to normalize naloxone possession and use, encourage shared responsibility for community health, and elicit empathy for people who use drugs. Taken together, participants' narratives hold implications for the following potential messaging content: (1) naloxone is short-acting, and withdrawal sickness does not have to be long-lasting; (2) it is critical to accurately identify an opioid-involved overdose; (3) anyone can overdose; (4) naloxone cannot do harm; and (5) the prompt administration of the medication can help ensure that someone can enjoy another day. Finally, participants suggested that messaging should also debunk myths and stereotypes about people who use drugs more generally; people who use opioids who reverse overdoses should be framed as lay public health advocates and not just "others" to be managed with stigmatizing practices and language.
conclusionsIt must be made a public health priority to get naloxone to people who use opioids who are best positioned to reverse an overdose, and to increase the likelihood that they will carry naloxone and use it when needed. Developing, tailoring, and deploying messages to address stigma, indifference toward overdose, fear and trepidation about reversing an overdose, and fear of police involvement may help alleviate fears among some people who are reluctant to obtain naloxone and use the medication on someone in an overdose situation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.